Synthesis and anticonvulsant activity of some N-phenyl-2- phtalimidoethanesulfonamide derivatives

Archiv der Pharmazie

Volumn 340, Issue 12, 2007, Pages 656-660

  Akgul, Ozlem ^a   Kilic, Fatma Sultan ^b   Erol, Kevser ^b   Pabuccuoglu, Varol ^a  

^a EGE UNIVERSITY   (Turkey)

^b ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Anticonvulsant; MES; N Phenyl 2 phtalimidoethanesulfonamide; Taltrimide; Taurine

Indexed keywords

ANILIDE; ANTICONVULSIVE AGENT; N PHENYL 2 PHTHALIMIDOETHANE SULFONAMIDE DERIVATIVE; SULFONAMIDE; TALTRIMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SYNTHESIS; ELECTRIC SHOCK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SINGLE DRUG DOSE;

ANIMALS; ANTICONVULSANTS; ELECTROSHOCK; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; PENTYLENETETRAZOLE; PHTHALIMIDES; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 37349003751     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700166     Document Type: Article

References (24)

1. th Ed., 2005, chapter 19.
2. W. Löscher, Eur. J. Pharm. 1998, 342, 1-13.
3. Z. Lin, P. K. Kabada, Med. Res. Rev. 1997, 17, 537-572.
4. M. J. Brodie, Epilepsy R. 2001, 45, 3-6.
5. P. Kwan, G. J. Sills, M. J. Brodie, Pharmcol. Ther. 2001, 90, 21-34.
6. B. K. Kohl, G. Dannhardt, Curr. Med. Chem. 2001, 8, 1275-1289.
7. I. Böhme, H. Lüddens, Curr. Med. Chem. 2001, 8, 1257-1274.
8. R. C. Gupta, T. Win, S. Bittner, Curr. Med. Chem. 2005, 12, 2021-2039.
9. A. El Idrissi, E. Trenkner, Neurochem. Res. 2004, 29, 189-197.
10. N. G. Bowery, T. G. Smart, Br. J. Pharmacol. 2006, 147, 109-119.
11. st Century Advances in Experimental Medicine and Biology, (Eds.: J. B. Lombardini, S. W. Schaffer, J. Azuma), New York, Kluwer Academic/Plenum Publ. 2003, 526, pp. 515-525.
12. L. Andersen, L. Sundman, I. Linden, P. Kontro, S. S. Oja, J. Pharm. Sci. 1984, 73, 106-108.
13. I.-B. Lindén, G. G. Kontro, S. S. Oja, Neurochem. Int. 1983, 5, 319-324.
14. K. Koivisto, J. Sivenius, T. Keranen, J. Partanen, et al., Epilepsia 1986, 27, 87-90.
15. N. Isoherranen, B. Yagen, O. Spiegelstein, R. H. Finnell, et al., British. J. Pharmacol. 2003, 139, 755-764.
16. V. Bailleux, L. Vallee, J. P. Nuyts, J. Vamecq, Biomed. Pharmacother. 1994, 48, 95-101.
17. V. Bailleux, L. Vallee, J. P. Nuyts, J. Vamecq, Chem. Pharm. Bull. 1994, 42, 1817-1821.
18. C. R. Clark, C. M. Lin, R. T. Sansom, J. Med. Chem. 1986, 29, 1534-1537.
19. R. Winterbottom, J. W. Clapp, W. H. Miller, J. P. English, R. O. Roblin, J. Am. Chem. Soc. 1947, 69, 1393-1401.
20. O. C. Usifoh, D. M. Labert, J. Wouters, G. K. E. Scriba, Arch. Pharm. Pharm. Med. Chem. 2001, 334, 323-331.
21. M. Hesse, H. Meier, B. Zeeh in Spectroscopic Methods in Organic Chemistry, (Eds.: D. Enders, R. Noyori, B. M. Trost), New York, Georg Thieme Verlag, Stuttgart, 1997.
22. J. P. Stables, H. J. Kupferberg in Molcular and Cellular Targets for Antiepileptic Drugs, (Eds.: G. Avazini, P. Tangelli, M. Avoli), London, John Libbey, 1997, pp. 191-198.
23. Z. Soyer, S. F. Kilic, K. Erol, V. Pabuccuoglu, Arch. Pharm. Pharm. Med. Chem. 2004, 337, 105-111.
24. H. Ucar, K. V. Derpoorten, S. Cacciaguerra, S. Spamnato, et al., J. Med. Chem. 1998, 41, 1138-1145.